Determination of Higher Order Structure and Hydrogen Deuterium Exchange by LC–MS - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Determination of Higher Order Structure and Hydrogen Deuterium Exchange by LC–MS
Hydrogen deuterium exchange by mass spectrometry is a powerful analytical approach that can be used to map higher order structures of proteins.


Pharmaceutical Technology
pp. s38-240

Comparability and biosimilarity

Comparability has been an important aspect of biotherapeutic development since the advent of the well-characterized biotherapeutic product guidelines established in the 1990s. These formalized FDA guidelines were a boon to the development of biotherapeutics because they offered a pragmatic pathway to characterizing multiple elements and trying to relate them to the clinic. As time has progressed, many default techniques, such as peptide mapping and glycan profiling, have become increasing automated. Indeed, the automation of these techniques routinely uncovers important issues such as sequence variation in biosimilar candidates or variations in glycosylation profiles (11, 16, 17).

With the advent of HDX–MS, the comparability toolbox can be extended further into the realm of HOS. Comparability in HOS was aptly demonstrated by a study of a commercial growth hormone that was covalently attached to a polyethylene glycol (PEG) polymer (i.e., PEGylated) (18, 19). In that study, the authors used HDX–MS to analyze granulocyte colony stimulating factor (G-CSF) upon PEGylation. PEGylation is known to reduce immunogenicity and antigenicity and may prolong circulating time (20). FDA has approved a number of biotherapeutics that are PEGylated, and many more are believed to be in the pipeline (18, 19).

PEGylation may induce conformational changes, steric interferences, and changes in electrostatic binding (21). The researchers performed a number of experiments to obtain an overall picture. Three undeuterated experiments and two complete HDX experiments were performed for each protein. In total, 10 separate experiments were performed for all forms of G-CSF within two consecutive days, which helps illustrate the importance of automation and robotics.

Significant differences in deuterium incorporation were induced by PEGylation of G-CSF, but the researchers concluded that the changes were quite small and that PEGylation did not result in gross conformational rearrangement of G-CSF (5). The raw differences between specific peptides in the protein chain were charted automatically; if the value of differences exceeded an empirically-determined amount (i.e., 1.5 Da), it was considered significant. The decisions about significant differences are also captured by performing triplicate acquisitions, thus providing a proper basis for judgment. Controls were also used with totally separate duplicate runs of G-CSF or PEGylated G-CSF to demonstrate that the differences observed in the plots of PEGylated versus non-PEGylated were real.

With HDX–MS, this type of study can be directly matched to clinical trial data, especially in situations for which it is known that HOS changes may occur. For this study, the authors commented that the data complexity was greatly reduced though a data processing and presentation format that was designed to facilitate their comparison process. The study demonstrated the immediate utility of HDX–MS for comparability studies as well as protein therapeutic characterization in the biopharmaceutical industry.

In 2012, FDA released guidelines on biosimilars that specifically called for studies of HOS, following earlier testimony to the US Congress (22, 23). Many national guidelines have, until now, tended to use an all-encompassing description such as "state-of-the-art" technology. The FDA guidelines of 2012 potentially reflect the rapidly expanding set of analytical tools for biotherapeutics, as well as an understanding that techniques to study HOS are increasingly routine.

Even in studies of insulin, which is an extremely well-characterized protein, there is recent evidence for the importance of characterizing HOS to match an innovator product's efficacy. In a case in which a biosimilar insulin was well-characterized, the primary structure, downstream processing aspects, and manufacturing processes were well understood. Unfortunately, the submission failed when clinical data indicated different pharmacokinetics that may well have been predicted by HOS studies (24). The need to characterize HOS is of worldwide concern, as is clear from the wide variety of geographies where such studies are taking place, including Japan (25).

Summary

HOS studies have benefitted greatly from advances in technology, informatics, and the robustness of the analytical LC–MS toolkit. In addition, the wider scientific understanding of what is achievable has meant a recent quantum leap in the demand for—and development of—HDX–MS. Like a genie released from its bottle, this powerful capability cannot be put back in the darkness. It will only continue to grow and further inform our understanding of protein biotherapeutics.

St. John Skilton, PhD, is senior manager of late-stage development for pharmaceutical life sciences at Waters, tel: 508.377.8234.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here